Neurological products and therapies news

Global engineering company Renishaw has built a device that has been used in a ground-breaking clinical trial. Manufactured by Renishaw on behalf of the North Bristol NHS Trust, the device enabled the precise delivery of a new drug candidate, Glial Cell Line Derived Neurotrophic Factor (GDNF) with the hope of regenerating dying dopamine brain cells in people with Parkinson’s and thereby improve their symptoms.

A new frameless patient registration module for the neuromate® surgical robot, the neurolocate™ 2D module, has obtained a CE mark. Global engineering company Renishaw will now offer the neurolocate 2D module to hospitals across Europe to help save time and costs by realising the benefits of intraoperative imaging.

At the 23rd congress of the European Society for Stereotactic and Functional Neurosurgery (ESSFN), global engineering company Renishaw will present its range of products for stereotactic neurosurgery. Held in Edinburgh, Scotland from September 26th to 29th, 2018, the event brings together neuroscientists, neurosurgeons and psychiatrists to discuss the latest advances in the field.

Renishaw, a global engineering company with expertise in healthcare, is exhibiting at the International Symposium on Paediatric Neuro-Oncology (ISPNO) 2018. From June 30th to July 3rd at the Hyatt Regency Hotel in Denver, Colorado, USA the company will showcase its neurological products which improve accuracy and reduce procedure time in neurosurgery.

From June 24th to June 27th, 2018, global engineering technologies company Renishaw will attend the Canadian Neurological Sciences Federation’s annual congress. The event, held at the Halifax Convention Centre, Nova Scotia, provides multidisciplinary courses relevant to all neuroscience specialities. On booth 304, Renishaw will showcase its neuromate® stereotactic robot and neuroinspire™ its surgical planning software.